Evidence map›Paper›PMID 27002787›Full record

ReviewAnnals of the New York Academy of Sciences2016

Multiple myeloma in the marrow: pathogenesis and treatments.

Heather Fairfield, Carolyne Falank, Lindsey Avery, Michaela R Reagan

Abstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 1 synthesis or guideline pooled it, 183 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.International journal of hematology-oncology and stem cell research · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Heather FairfieldMaine Medical Center Research Institute, Scarborough, Maine.
Carolyne FalankMaine Medical Center Research Institute, Scarborough, Maine.
Lindsey AveryUniversity of Maine, Orono, Maine.
Michaela R ReaganMaine Medical Center Research Institute, Scarborough, Maine.
Maine Medical Center Research Institute · USUniversity of Maine · US

Funding

Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy BalanceR24DK092759 · NIDDK · MAINEHEALTH · PI HOROWITZ, MARK C, MACDOUGALD, ORMOND A · 2011 to 2019
$13.0M
Progenitor Cell Analysis CoreP30GM106391 · NIGMS · MAINEHEALTH · PI WOJCHOWSKI, DON MICHAEL · 2013 to 2017
$5.7M
NIDDK NIH HHS R24 DK092759NIDDK NIH HHS R24DK092759-01NIGMS NIH HHS P30 GM106391NIGMS NIH HHS P30GM106391
6 · The paper itself

Abstract

Multiple myeloma (MM) is a B cell malignancy resulting in osteolytic lesions and fractures. In the disease state, bone healing is limited owing to increased osteoclastic and decreased osteoblastic activity, as well as an MM-induced forward-feedback cycle where bone-embedded growth factors further enhance tumor progression as bone is resorbed. Recent work on somatic mutation in MM tumors has provided insight into cytogenetic changes associated with this disease; the initiating driver mutations causing MM are diverse because of the complexity and multitude of mutations inherent in MM tumor cells. This manuscript provides an overview of MM pathogenesis by summarizing cytogenic changes related to oncogenes and tumor suppressors associated with MM, reviewing risk factors, and describing the disease progression from monoclonal gammopathy of undetermined significance to overt MM. It also highlights the importance of the bone marrow microenvironment (BMM) in the establishment and progression of MM, as well as associated MM-induced bone disease, and the relationship of the bone marrow to current and future therapeutics. This review highlights why understanding the basic biology of the healthy and diseased BMM is crucial in the quest for better treatments and work toward a cure for genetically diverse diseases such as MM.

Indexed as

Models, BiologicalTumor MicroenvironmentAnimalsAntineoplastic AgentsBone MarrowBone Marrow CellsBone RemodelingHumansMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaMutationNeoplasm ProteinsPrecision MedicineStem Cell NicheStem Cell TransplantationTransplantation, AutologousAntineoplastic AgentsNeoplasm Proteinsbone marrowbone marrow nicheFairfield, H., C. Falank, L. Avery & M. R. Reagan. 2016. Multiple myeloma in the marrow: pathogenesis and treatments. In “MARROW,” ed. by M. Zaidi. Ann. N.Y. Acad. Sci. 1364: 32-51.multiple myelomatreatments

Identifiers

PMID27002787
PMCPMC4806534
OpenAlexW2308917761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.